| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 66 | 2024 | 4946 | 4.850 |
Why?
|
| Anti-HIV Agents | 33 | 2024 | 1275 | 3.660 |
Why?
|
| Anti-Retroviral Agents | 17 | 2023 | 542 | 2.500 |
Why?
|
| Pregnancy Complications, Infectious | 12 | 2024 | 507 | 1.950 |
Why?
|
| Antiretroviral Therapy, Highly Active | 14 | 2020 | 468 | 1.780 |
Why?
|
| Humans | 88 | 2024 | 14077 | 1.750 |
Why?
|
| Female | 61 | 2024 | 8751 | 1.520 |
Why?
|
| Pregnancy | 28 | 2024 | 1815 | 1.430 |
Why?
|
| Child | 34 | 2024 | 2180 | 1.360 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 9 | 2024 | 76 | 1.170 |
Why?
|
| Antitubercular Agents | 7 | 2020 | 299 | 1.160 |
Why?
|
| HIV-1 | 12 | 2024 | 1239 | 1.130 |
Why?
|
| Ritonavir | 8 | 2021 | 137 | 1.100 |
Why?
|
| Oxazines | 9 | 2024 | 71 | 1.060 |
Why?
|
| Pyridones | 9 | 2024 | 87 | 1.050 |
Why?
|
| Viral Load | 15 | 2023 | 808 | 1.020 |
Why?
|
| Adolescent | 23 | 2023 | 2858 | 0.990 |
Why?
|
| Child, Preschool | 27 | 2023 | 1675 | 0.980 |
Why?
|
| Drug Resistance, Viral | 5 | 2024 | 268 | 0.970 |
Why?
|
| Adult | 32 | 2024 | 5664 | 0.880 |
Why?
|
| Lost to Follow-Up | 3 | 2018 | 62 | 0.870 |
Why?
|
| Lamivudine | 5 | 2024 | 86 | 0.860 |
Why?
|
| HIV Seropositivity | 3 | 2022 | 263 | 0.850 |
Why?
|
| Piperazines | 8 | 2024 | 73 | 0.840 |
Why?
|
| South Africa | 31 | 2024 | 7312 | 0.840 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 5 | 2021 | 210 | 0.830 |
Why?
|
| Male | 35 | 2024 | 6489 | 0.820 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 70 | 0.810 |
Why?
|
| Infant | 25 | 2024 | 2145 | 0.810 |
Why?
|
| Infectious Disease Transmission, Vertical | 9 | 2024 | 467 | 0.800 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 102 | 0.800 |
Why?
|
| HIV | 7 | 2021 | 380 | 0.800 |
Why?
|
| Tenofovir | 10 | 2024 | 158 | 0.780 |
Why?
|
| Vaccines | 4 | 2024 | 84 | 0.780 |
Why?
|
| Pregnancy Outcome | 7 | 2024 | 112 | 0.770 |
Why?
|
| Asymptomatic Infections | 2 | 2021 | 29 | 0.760 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 186 | 0.700 |
Why?
|
| Sentinel Surveillance | 1 | 2020 | 110 | 0.690 |
Why?
|
| Patient Compliance | 3 | 2018 | 120 | 0.650 |
Why?
|
| Tuberculosis | 5 | 2021 | 530 | 0.650 |
Why?
|
| Treatment Outcome | 17 | 2021 | 867 | 0.640 |
Why?
|
| Immunogenicity, Vaccine | 5 | 2022 | 91 | 0.620 |
Why?
|
| Benzoxazines | 7 | 2024 | 119 | 0.620 |
Why?
|
| Ambulatory Care | 1 | 2018 | 54 | 0.610 |
Why?
|
| Genes, Viral | 1 | 2017 | 11 | 0.600 |
Why?
|
| Emtricitabine | 9 | 2024 | 74 | 0.590 |
Why?
|
| Maternal Health | 4 | 2021 | 18 | 0.560 |
Why?
|
| Premature Birth | 3 | 2024 | 76 | 0.540 |
Why?
|
| Salvage Therapy | 1 | 2015 | 6 | 0.520 |
Why?
|
| Lopinavir | 6 | 2020 | 137 | 0.510 |
Why?
|
| Rifampin | 5 | 2021 | 189 | 0.510 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2021 | 326 | 0.510 |
Why?
|
| CD4 Lymphocyte Count | 11 | 2021 | 654 | 0.510 |
Why?
|
| Sulfonamides | 1 | 2015 | 10 | 0.500 |
Why?
|
| Young Adult | 16 | 2024 | 2357 | 0.500 |
Why?
|
| Infant, Newborn | 14 | 2024 | 1410 | 0.500 |
Why?
|
| Adenine | 5 | 2024 | 88 | 0.490 |
Why?
|
| Postpartum Period | 3 | 2024 | 78 | 0.490 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2015 | 145 | 0.480 |
Why?
|
| Breast Feeding | 4 | 2024 | 119 | 0.470 |
Why?
|
| Bacteriological Techniques | 1 | 2014 | 54 | 0.460 |
Why?
|
| Retrospective Studies | 8 | 2024 | 767 | 0.450 |
Why?
|
| Alkynes | 6 | 2024 | 113 | 0.450 |
Why?
|
| Cyclopropanes | 6 | 2024 | 119 | 0.450 |
Why?
|
| Coinfection | 2 | 2018 | 268 | 0.430 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 265 | 0.410 |
Why?
|
| Clinical Trials as Topic | 5 | 2021 | 112 | 0.410 |
Why?
|
| Antibodies, Neutralizing | 7 | 2023 | 285 | 0.410 |
Why?
|
| Health Personnel | 3 | 2023 | 229 | 0.390 |
Why?
|
| Antibodies, Viral | 5 | 2023 | 266 | 0.360 |
Why?
|
| Nevirapine | 3 | 2021 | 146 | 0.350 |
Why?
|
| Pandemics | 3 | 2023 | 280 | 0.350 |
Why?
|
| Prospective Studies | 9 | 2020 | 1131 | 0.340 |
Why?
|
| Cross-Sectional Studies | 4 | 2022 | 1377 | 0.330 |
Why?
|
| Neurodevelopmental Disorders | 2 | 2019 | 7 | 0.330 |
Why?
|
| Follow-Up Studies | 4 | 2018 | 367 | 0.330 |
Why?
|
| HIV Protease Inhibitors | 3 | 2015 | 92 | 0.330 |
Why?
|
| Middle Aged | 13 | 2024 | 3425 | 0.330 |
Why?
|
| Uganda | 4 | 2022 | 194 | 0.320 |
Why?
|
| Neurocognitive Disorders | 2 | 2019 | 13 | 0.320 |
Why?
|
| Disease Management | 2 | 2019 | 73 | 0.300 |
Why?
|
| Drug Therapy, Combination | 6 | 2021 | 271 | 0.280 |
Why?
|
| Stillbirth | 3 | 2024 | 81 | 0.280 |
Why?
|
| Weight Gain | 2 | 2024 | 73 | 0.280 |
Why?
|
| Pyrimidines | 2 | 2023 | 29 | 0.270 |
Why?
|
| Medication Adherence | 3 | 2017 | 137 | 0.270 |
Why?
|
| Prevalence | 3 | 2022 | 1149 | 0.270 |
Why?
|
| Seroepidemiologic Studies | 2 | 2023 | 104 | 0.260 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 163 | 0.260 |
Why?
|
| Drug Interactions | 3 | 2021 | 30 | 0.250 |
Why?
|
| Immunoglobulin G | 5 | 2023 | 220 | 0.240 |
Why?
|
| Caregivers | 3 | 2022 | 66 | 0.240 |
Why?
|
| Consent Forms | 1 | 2024 | 2 | 0.230 |
Why?
|
| Informed Consent | 1 | 2024 | 8 | 0.230 |
Why?
|
| Electronics | 1 | 2023 | 2 | 0.230 |
Why?
|
| Time Factors | 5 | 2020 | 503 | 0.230 |
Why?
|
| Maternal Death | 1 | 2024 | 25 | 0.230 |
Why?
|
| Research Design | 3 | 2021 | 123 | 0.220 |
Why?
|
| Contraceptive Devices, Female | 1 | 2023 | 29 | 0.220 |
Why?
|
| Double-Blind Method | 5 | 2021 | 263 | 0.220 |
Why?
|
| Betacoronavirus | 2 | 2020 | 51 | 0.220 |
Why?
|
| Diabetes, Gestational | 1 | 2024 | 35 | 0.220 |
Why?
|
| Streptococcal Vaccines | 1 | 2023 | 45 | 0.220 |
Why?
|
| Point-of-Care Testing | 1 | 2023 | 68 | 0.220 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2020 | 56 | 0.210 |
Why?
|
| Immunization | 2 | 2020 | 63 | 0.210 |
Why?
|
| Dideoxynucleosides | 2 | 2020 | 29 | 0.200 |
Why?
|
| Viral Vaccines | 1 | 2022 | 21 | 0.200 |
Why?
|
| Alanine | 4 | 2024 | 29 | 0.200 |
Why?
|
| Pregnant Women | 1 | 2022 | 89 | 0.200 |
Why?
|
| Mass Screening | 2 | 2021 | 242 | 0.200 |
Why?
|
| Practice Guidelines as Topic | 3 | 2019 | 123 | 0.200 |
Why?
|
| Pyridazines | 1 | 2021 | 5 | 0.190 |
Why?
|
| Streptococcus agalactiae | 1 | 2023 | 197 | 0.190 |
Why?
|
| Milk, Human | 1 | 2021 | 22 | 0.190 |
Why?
|
| Survival Analysis | 2 | 2018 | 149 | 0.190 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2021 | 5 | 0.190 |
Why?
|
| Drug Substitution | 2 | 2019 | 29 | 0.190 |
Why?
|
| Perinatal Mortality | 1 | 2021 | 11 | 0.190 |
Why?
|
| Nanoparticles | 1 | 2022 | 104 | 0.190 |
Why?
|
| Congenital Abnormalities | 1 | 2021 | 7 | 0.190 |
Why?
|
| Malawi | 4 | 2024 | 86 | 0.190 |
Why?
|
| Placenta | 1 | 2021 | 43 | 0.190 |
Why?
|
| Streptococcal Infections | 1 | 2023 | 179 | 0.190 |
Why?
|
| Folic Acid | 1 | 2021 | 12 | 0.190 |
Why?
|
| Treatment Failure | 5 | 2021 | 175 | 0.180 |
Why?
|
| Cohort Studies | 7 | 2018 | 939 | 0.180 |
Why?
|
| Immunization, Secondary | 1 | 2021 | 62 | 0.180 |
Why?
|
| Drug Costs | 2 | 2018 | 18 | 0.180 |
Why?
|
| Immunization Schedule | 1 | 2021 | 70 | 0.180 |
Why?
|
| Vaccination | 4 | 2023 | 347 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2023 | 237 | 0.180 |
Why?
|
| Child Development | 1 | 2021 | 89 | 0.180 |
Why?
|
| Mutation | 2 | 2021 | 299 | 0.180 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 11 | 0.180 |
Why?
|
| Vaccines, Subunit | 1 | 2020 | 8 | 0.180 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2020 | 11 | 0.180 |
Why?
|
| Research | 1 | 2020 | 65 | 0.170 |
Why?
|
| Rotavirus | 1 | 2020 | 29 | 0.170 |
Why?
|
| Occupational Exposure | 1 | 2020 | 35 | 0.170 |
Why?
|
| United States | 2 | 2020 | 129 | 0.170 |
Why?
|
| Age Factors | 3 | 2018 | 364 | 0.170 |
Why?
|
| Phosphorous Acids | 1 | 2019 | 14 | 0.170 |
Why?
|
| Attitude of Health Personnel | 2 | 2022 | 102 | 0.170 |
Why?
|
| Executive Function | 1 | 2019 | 23 | 0.170 |
Why?
|
| Risk Factors | 4 | 2020 | 1431 | 0.170 |
Why?
|
| Rotavirus Vaccines | 1 | 2020 | 53 | 0.170 |
Why?
|
| Data Collection | 1 | 2019 | 86 | 0.170 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2019 | 19 | 0.160 |
Why?
|
| Tuberculosis, Pulmonary | 2 | 2020 | 320 | 0.160 |
Why?
|
| Prenatal Care | 1 | 2020 | 141 | 0.160 |
Why?
|
| Levofloxacin | 1 | 2018 | 15 | 0.160 |
Why?
|
| Ambulatory Care Facilities | 2 | 2024 | 125 | 0.160 |
Why?
|
| Registries | 1 | 2019 | 89 | 0.160 |
Why?
|
| Mental Health | 2 | 2020 | 86 | 0.160 |
Why?
|
| Contact Tracing | 1 | 2018 | 47 | 0.160 |
Why?
|
| Obesity | 1 | 2021 | 356 | 0.160 |
Why?
|
| Depression | 1 | 2019 | 117 | 0.150 |
Why?
|
| Long-Term Care | 1 | 2017 | 13 | 0.150 |
Why?
|
| Logistic Models | 2 | 2019 | 252 | 0.150 |
Why?
|
| Drug Monitoring | 1 | 2017 | 55 | 0.150 |
Why?
|
| Gestational Age | 3 | 2024 | 78 | 0.150 |
Why?
|
| Therapeutic Equipoise | 1 | 2017 | 4 | 0.140 |
Why?
|
| Cost Savings | 1 | 2016 | 6 | 0.140 |
Why?
|
| Patient Selection | 1 | 2017 | 40 | 0.140 |
Why?
|
| Africa | 3 | 2024 | 360 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2017 | 48 | 0.140 |
Why?
|
| Primary Health Care | 1 | 2018 | 228 | 0.130 |
Why?
|
| Zimbabwe | 3 | 2021 | 115 | 0.130 |
Why?
|
| Aged | 4 | 2021 | 1650 | 0.130 |
Why?
|
| Physicians | 1 | 2016 | 30 | 0.130 |
Why?
|
| Darunavir | 1 | 2015 | 12 | 0.130 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2015 | 33 | 0.130 |
Why?
|
| Unsafe Sex | 1 | 2015 | 45 | 0.120 |
Why?
|
| Health Education | 1 | 2015 | 35 | 0.120 |
Why?
|
| Reproductive Health | 1 | 2015 | 51 | 0.120 |
Why?
|
| Social Support | 1 | 2015 | 76 | 0.120 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2014 | 17 | 0.120 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 45 | 0.120 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 29 | 0.120 |
Why?
|
| Africa, Southern | 3 | 2020 | 89 | 0.120 |
Why?
|
| Odds Ratio | 1 | 2014 | 132 | 0.110 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 171 | 0.110 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 183 | 0.110 |
Why?
|
| Pediatrics | 1 | 2013 | 16 | 0.110 |
Why?
|
| World Health Organization | 3 | 2022 | 134 | 0.110 |
Why?
|
| Drug Combinations | 3 | 2020 | 41 | 0.110 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2014 | 184 | 0.110 |
Why?
|
| Stavudine | 1 | 2013 | 78 | 0.100 |
Why?
|
| Spike Glycoprotein, Coronavirus | 2 | 2023 | 84 | 0.100 |
Why?
|
| Health Care Costs | 1 | 2013 | 107 | 0.100 |
Why?
|
| T-Lymphocytes | 2 | 2022 | 59 | 0.100 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2023 | 20 | 0.100 |
Why?
|
| Qualitative Research | 2 | 2023 | 294 | 0.100 |
Why?
|
| Mycobacterium | 1 | 2011 | 16 | 0.090 |
Why?
|
| Zidovudine | 2 | 2022 | 59 | 0.090 |
Why?
|
| Pyrimidinones | 1 | 2011 | 24 | 0.090 |
Why?
|
| Ultrasonography, Prenatal | 2 | 2021 | 24 | 0.090 |
Why?
|
| Antibody Formation | 2 | 2021 | 61 | 0.090 |
Why?
|
| Drug Administration Schedule | 2 | 2019 | 153 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 2 | 2018 | 22 | 0.080 |
Why?
|
| Incidence | 2 | 2020 | 655 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 243 | 0.070 |
Why?
|
| Surveys and Questionnaires | 2 | 2019 | 532 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 2 | 2018 | 235 | 0.060 |
Why?
|
| India | 1 | 2024 | 60 | 0.060 |
Why?
|
| Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | 1 | 2023 | 2 | 0.060 |
Why?
|
| Patient Preference | 1 | 2023 | 22 | 0.060 |
Why?
|
| Receptors, Fc | 1 | 2023 | 10 | 0.060 |
Why?
|
| Vaccines, Combined | 1 | 2023 | 34 | 0.060 |
Why?
|
| Cognition | 1 | 2024 | 75 | 0.050 |
Why?
|
| RNA | 1 | 2023 | 26 | 0.050 |
Why?
|
| Antibodies, Blocking | 1 | 2023 | 9 | 0.050 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 2023 | 40 | 0.050 |
Why?
|
| Immunoglobulin A | 1 | 2023 | 39 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 409 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 60 | 0.050 |
Why?
|
| Immunity, Humoral | 1 | 2022 | 42 | 0.050 |
Why?
|
| Phosphates | 1 | 2022 | 10 | 0.050 |
Why?
|
| Vaccines, Conjugate | 1 | 2023 | 161 | 0.050 |
Why?
|
| Antibodies, Bacterial | 1 | 2023 | 149 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 1 | 2022 | 21 | 0.050 |
Why?
|
| Calcium | 1 | 2022 | 49 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2024 | 312 | 0.050 |
Why?
|
| Nitriles | 1 | 2021 | 27 | 0.050 |
Why?
|
| Cross Reactions | 1 | 2021 | 44 | 0.050 |
Why?
|
| Safety | 1 | 2021 | 34 | 0.050 |
Why?
|
| Policy | 1 | 2021 | 42 | 0.050 |
Why?
|
| Raltegravir Potassium | 1 | 2021 | 14 | 0.050 |
Why?
|
| Vaccine Potency | 1 | 2021 | 16 | 0.050 |
Why?
|
| HIV Seronegativity | 1 | 2021 | 52 | 0.050 |
Why?
|
| Infant, Low Birth Weight | 1 | 2021 | 33 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2020 | 17 | 0.050 |
Why?
|
| Brazil | 1 | 2020 | 43 | 0.050 |
Why?
|
| Adenoviridae | 1 | 2021 | 39 | 0.050 |
Why?
|
| United Kingdom | 1 | 2020 | 32 | 0.050 |
Why?
|
| Family Characteristics | 1 | 2021 | 133 | 0.050 |
Why?
|
| Maternal Mortality | 1 | 2021 | 54 | 0.050 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 16 | 0.040 |
Why?
|
| Biological Availability | 1 | 2020 | 43 | 0.040 |
Why?
|
| Infection Control | 1 | 2020 | 31 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2020 | 19 | 0.040 |
Why?
|
| Schools | 1 | 2020 | 67 | 0.040 |
Why?
|
| Body Weight | 1 | 2020 | 110 | 0.040 |
Why?
|
| ROC Curve | 1 | 2020 | 47 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 37 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 449 | 0.040 |
Why?
|
| Models, Biological | 1 | 2020 | 77 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 42 | 0.040 |
Why?
|
| Uracil | 1 | 2019 | 7 | 0.040 |
Why?
|
| Risk | 1 | 2019 | 87 | 0.040 |
Why?
|
| Prodrugs | 1 | 2019 | 10 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2019 | 21 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 111 | 0.040 |
Why?
|
| Algorithms | 1 | 2020 | 105 | 0.040 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2019 | 29 | 0.040 |
Why?
|
| Body Composition | 1 | 2020 | 150 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 210 | 0.040 |
Why?
|
| Mortality | 1 | 2020 | 101 | 0.040 |
Why?
|
| Central America | 1 | 2018 | 1 | 0.040 |
Why?
|
| Caribbean Region | 1 | 2018 | 11 | 0.040 |
Why?
|
| South America | 1 | 2018 | 26 | 0.040 |
Why?
|
| Housing | 1 | 2018 | 24 | 0.040 |
Why?
|
| Asia | 1 | 2018 | 70 | 0.040 |
Why?
|
| Bone Density | 1 | 2019 | 103 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2018 | 64 | 0.040 |
Why?
|
| Child Nutrition Disorders | 1 | 2018 | 10 | 0.040 |
Why?
|
| Age of Onset | 1 | 2018 | 32 | 0.040 |
Why?
|
| Disease Progression | 1 | 2018 | 154 | 0.040 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 2018 | 19 | 0.040 |
Why?
|
| Quality Assurance, Health Care | 1 | 2018 | 43 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2019 | 303 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2019 | 155 | 0.040 |
Why?
|
| Malnutrition | 1 | 2018 | 53 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2018 | 55 | 0.040 |
Why?
|
| Nutritional Status | 1 | 2018 | 75 | 0.040 |
Why?
|
| Comorbidity | 1 | 2018 | 184 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2018 | 217 | 0.040 |
Why?
|
| Africa South of the Sahara | 1 | 2018 | 328 | 0.040 |
Why?
|
| Uncertainty | 1 | 2017 | 7 | 0.040 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2017 | 9 | 0.040 |
Why?
|
| Drug Discovery | 1 | 2016 | 22 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 41 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 103 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2016 | 25 | 0.030 |
Why?
|
| Family | 1 | 2016 | 33 | 0.030 |
Why?
|
| Global Health | 1 | 2017 | 183 | 0.030 |
Why?
|
| Tuberculosis, Lymph Node | 1 | 2015 | 8 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2015 | 65 | 0.030 |
Why?
|
| Parents | 1 | 2013 | 29 | 0.030 |
Why?
|
| Genotype | 1 | 2015 | 430 | 0.030 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2016 | 171 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2013 | 34 | 0.030 |
Why?
|
| Thinness | 1 | 2013 | 18 | 0.030 |
Why?
|
| Risk Adjustment | 1 | 2011 | 3 | 0.020 |
Why?
|
| Drug Dosage Calculations | 1 | 2011 | 8 | 0.020 |
Why?
|
| Polypharmacy | 1 | 2011 | 5 | 0.020 |
Why?
|
| Hospitalization | 1 | 2013 | 392 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 124 | 0.020 |
Why?
|